Triumvira Immunologics announced a $55 million Series A round co-led by Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures. Additional investors include Oceanpine Capital and Viva Biotech Holdings, and existing investors include Bloom Burton & Co. and the Centre for Commercialization of Cancer Immunotherapy (C3i). Triumvira will use the funding to run clinical trials of cell therapies that are directed by an alternative to CARs.